Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT01710644 is registered in ClinicalTrials.gov with Nordmark Arzneimittel GmbH & Co. KG as lead sponsor.

NCT NCT01710644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01710644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Lead sponsor
Nordmark Arzneimittel GmbH & Co. KG
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2013
Completion date
August 31, 2014
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, digestive system diseases, lung diseases, pancreatic insufficiency, respiratory tract diseases